PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.09%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
3.56%
G&A change of 3.56% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-26.91%
Operating expenses reduction while Biotechnology median is 3.78%. Seth Klarman would investigate advantages.
-26.91%
Total costs reduction while Biotechnology median is 3.01%. Seth Klarman would investigate advantages.
10.26%
Interest expense change of 10.26% versus flat Biotechnology costs. Walter Schloss would verify control.
-96.48%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-115.63%
EBITDA decline while Biotechnology median is -1.31%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
27.06%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-198.08%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-304.05%
Pre-tax income decline while Biotechnology median is -0.06%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
113.79%
Tax expense change of 113.79% versus flat Biotechnology. Walter Schloss would verify strategy.
-304.05%
Net income decline while Biotechnology median is -1.46%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-302.06%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-288.66%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
0.11%
Share count change of 0.11% versus stable Biotechnology. Walter Schloss would verify approach.
3.68%
Diluted share change of 3.68% versus stable Biotechnology. Walter Schloss would verify approach.